Brazil's Public Health System May Offer Injected HIV Prevention This Year
Brazil's Unified Health System (SUS) may begin offering a new form of injectable pre-exposure prophylaxis (PrEP) for HIV prevention as early as this year. The medication is cabotegravir, which prevents the virus from replicating over an extended period and can be administered every two months.
The Ministry of Health will submit a request for inclusion to the National Commission for Incorporation of New Technologies in the SUS (Conitec) next week. Conitec is an independent committee that must evaluate aspects such as the cost-benefit of offering new treatments through public services before they are added to the SUS formulary.
The commission may recommend or reject inclusion, but the final decision rests with the Ministry. According to Health Minister Alexandre Padilha, the government is still negotiating with pharmaceutical company GSK, the producer of cabotegravir, over the final cost of the medication and how many doses will be purchased, but the company has made an offer with an "adequate price."
"We see new extended-protection technologies with great hope, but we demand that they be offered, especially to our national health systems, at adequate prices, not stratospheric prices," the minister said at a press conference before the opening of the 26th International AIDS Conference in Rio de Janeiro.
Lenacapavir
According to Padilha, cost was the determining factor in the government's choice of the injectable PrEP it plans to offer. Another medication, called lenacapavir, provides even longer protection—for six months—but was offered at an unfeasible price, the minister said.
"Even with Brazil willing to pay up to 10 times the amount that was offered to countries similar to ours, such as Indonesia and Thailand, the industry still said it cannot offer it to the national public system at that price. So we will not pay. We will not drain the resources from Brazilian taxpayers' taxes for the profit interest of a company."
Despite being one of the countries where the medication was tested, Brazil was excluded from the voluntary licensing agreement signed by pharmaceutical company Gilead, which authorized six companies to produce generic versions of lenacapavir for distribution in 120 countries.
The measure was criticized by other participants at the Conference, including the Joint United Nations Programme on HIV/AIDS (UNAIDS), because lenacapavir is considered central to ending the AIDS epidemic, and organizations involved in the issue argue that access to the medication should be expanded worldwide.
The pharmaceutical company stated in a note that it shares the urgency of expanding access to lenacapavir throughout Latin America and the Caribbean, but that "for countries outside the voluntary licensing territory, such as Brazil, it continues to seek sustainable long-term access pathways, aligned with local market conditions and public health priorities."
According to the note released by Gilead after statements made at the event, "Brazil is one of the priorities among countries evaluated as potential manufacturing partners." For this reason, the pharmaceutical company signed a memorandum of understanding with the Oswaldo Cruz Foundation "to explore potential opportunities for technology transfer that could support access in Brazil and throughout the region."
Oral PrEP
The Unified Health System already offers PrEP, but in oral form, as tablets that must be taken daily. More than 350,000 people have already had access to the medication, which also has proven efficacy.
The main advantage of injectable PrEP over the oral version is treatment adherence, since the tablets must be taken every day to ensure their effect. A Fiocruz study conducted with 1,400 people in six Brazilian cities showed that 83 percent preferred the injection.
In addition, 94 percent of participants came to the health service to receive injections on schedule, which ensured they remained protected throughout treatment. None of them were infected with the virus.
Another real-world study released by pharmaceutical companies ViiV Healthcare and GSK, which developed the medication, demonstrated high efficacy, with an annual HIV infection rate of only 0.1 percent.
